The estimated numbers of new occurrences and deaths in 2016 in the United States due to cancers of the oral cavity, pharynx and larynx are 61,760 and 13,190, respectively.1 Single-modality therapy is used for localized head and neck cancer (HNC), whereas multimodality therapy is used for locoregionally advanced disease. Goals of care are improved organ preservation and reduced cancer mortality. Surgery, radiotherapy, and systemic chemotherapy can result in short-term and long-term adverse effects that need to be managed among those who survive HNC. These HNC survivors have unmet needs as a result of toxicity from their disease and treatment, and guidelines are required to optimize their primary health care and to enable the preservation of their quality of life.2 In addition, increasing incidence of human papillomavirus (HPV)-related HNC, primarily in the oropharynx, has been observed in the past few decades,3 and it is associated with a more favorable prognosis than HNC associated with other risk factors, such as smoking. Hence, as the survival rates of HNC improve, the care of HNC survivors may be transitioned over time from their treating oncology team to primary care clinicians. Guidance and recommendations to enable optimal management of HNC survivors, particularly by primary care clinicians, are needed.